Oxford Biomedica Reports Strong Momentum and Reaffirms Financial Guidance

Oxford BioMedica ( (GB:OXB) ) has shared an update.

Oxford Biomedica, a leader in cell and gene therapy manufacturing, reports strong commercial momentum and operational progress in 2025, maintaining its financial guidance and outlook set earlier this year. The company continues to support clients across development stages, with no new material information disclosed at the AGM, reinforcing confidence in its near and medium-term targets.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Spark’s Take on GB:OXB Stock

According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.

Oxford BioMedica’s stock score reflects strong earnings call sentiment and positive technical indicators, tempered by financial instability and challenging valuation. Corporate events offer additional support, but profitability concerns remain significant risks.

To see Spark’s full report on GB:OXB stock, click here.

More about Oxford BioMedica

OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide expertise in viral vector development and manufacturing. The company offers a range of unique technologies and operates facilities in the UK, France, and the US.

Average Trading Volume: 255,197

Technical Sentiment Signal: Sell

Current Market Cap: £364.4M

See more data about OXB stock on TipRanks’ Stock Analysis page.